NAS:XENE (Canada) Also trade in: Germany

Xenon Pharmaceuticals Inc

$ 8.78 -0.12 (-1.35%)
Volume: 103,956 Avg Vol (1m): 67,878
Market Cap $: 226.31 Mil Enterprise Value $: 414.73 Mil
P/E (TTM): 0.00 P/B: 0.00
Earnings Power Value -245.91
Net Current Asset Value -7.51
Tangible Book -7.41
Projected FCF -4.94
Median P/S Value 0
Graham Number 0
Peter Lynch Value 0
DCF (FCF Based) 0
DCF (Earnings Based) 0
1Y (-%)

Financial Strength : 6/10

GuruFocus Financial Strength Rank measures how strong a company's financial situation is . It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
Current vs industry vs history
Cash-to-Debt 6.20
Cash-To-Debt range over the past 10 years
Min: 5.1, Med: 10000, Max: 10000
Current: 6.2
5.1
10000
Debt-to-Equity 0.20
Debt-to-Equity range over the past 10 years
Min: -0.02, Med: 0.18, Max: 0.24
Current: 0.2
-0.02
0.24
Debt-to-EBITDA -0.39
Debt-to-EBITDA range over the past 10 years
Min: -0.49, Med: -0.46, Max: -0.23
Current: -0.39
-0.49
-0.23
Piotroski F-Score 2
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 2.73
DISTRESS
GREY
SAFE
Beneish M-Score 99999999.99
Not Manipulator
Manipulator
WACC vs ROIC %
ROIC 0%
WACC 8.9%

Profitability & Growth : 2/10

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
Current vs industry vs history
ROE % -47.12
ROE range over the past 10 years
Min: -61.51, Med: -41.12, Max: -23.54
Current: -47.12
-61.51
-23.54
ROA % -41.10
ROA range over the past 10 years
Min: -54.05, Med: -20.81, Max: 20.43
Current: -41.1
-54.05
20.43
ROC (Joel Greenblatt) % -2684.19
ROC (Joel Greenblatt) range over the past 10 years
Min: -3212.32, Med: -419.31, Max: 539.88
Current: -2684.19
-3212.32
539.88
3-Year Total Revenue Growth Rate -100.00
3-Year Revenue Growth Rate range over the past 10 years
Min: -100, Med: -79.2, Max: 29.7
Current: -100
-100
29.7
3-Year Total EBITDA Growth Rate -57.50
N/A
3-Year EPS w/o NRI Growth Rate -14.00
N/A

Ratios

Current vs industry vs history
EV-to-EBIT -9.76
EV-to-EBIT range over the past 10 years
Min: -11.4, Med: -2.6, Max: 50.2
Current: -9.76
-11.4
50.2
EV-to-EBITDA -9.86
EV-to-EBITDA range over the past 10 years
Min: -13.3, Med: -2.7, Max: 42
Current: -9.86
-13.3
42
Current Ratio 11.07
Current Ratio range over the past 10 years
Min: 2.62, Med: 13.95, Max: 29.48
Current: 11.07
2.62
29.48
Quick Ratio 11.07
Quick Ratio range over the past 10 years
Min: 2.62, Med: 13.95, Max: 29.48
Current: 11.07
2.62
29.48

Dividend & Buy Back

Current vs industry vs history
3-Year Share Buyback Rate -20.60
3-Year Share Buyback Rate range over the past 10 years
Min: -104.1, Med: -88.8, Max: -8.3
Current: -20.6
-104.1
-8.3

Valuation & Return

Current vs industry vs history
Earnings Yield (Joel Greenblatt) % -10.24
Earnings Yield (Greenblatt) range over the past 10 years
Min: -8117.4, Med: -28.3, Max: 5221.5
Current: -10.24
-8117.4
5221.5

» XENE's 30-Y Financials

Financials (Next Earnings Date: 2019-11-06)

» Interactive Chart

Peter Lynch Chart

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with NAS:XENE

Business Description

Industry Biotechnology » Biotechnology    NAICS : 325412    SIC : 3741
Compare NAS:PTGX NAS:TOCA XTAE:KMDA NAS:XFOR XTER:MDG1 NAS:CNCE NAS:UROV NAS:ATHX XBRU:CYAD NAS:CERC NAS:NVAX NAS:MRSN NAS:CALA NAS:MRKR SHSE:603139 TPE:1760 AMEX:OCX NAS:STRO AMEX:XXII NAS:PETX
Traded in other countries XP0.Germany
Address 200-3650 Gilmore Way, Burnaby, BC, CAN, V5G 4W8
Xenon Pharmaceuticals Inc is a Canadian clinical-stage biopharmaceutical company. It is engaged in discovering and developing a pipeline of therapeutics for orphan indications. The company has developed a gene therapy referred as Glybera for the treatment of a subset of patients with the orphan lipid disorder lipoprotein lipase deficiency. The other product candidates include TV-45070, GDC-0310, XEN801 and XEN901 and other compounds in preclinical and discovery pipeline.

More Statistics

Analyst Estimate

Piotroski F-Score Details

Piotroski F-Score 2
Positive ROA N
Positive CFROA N
Higher ROA yoy N
CFROA > ROA Y
Lower Leverage yoy Y
Higher Current Ratio yoy N
Less Shares Outstanding yoy N
Higher Gross Margin yoy N
Higher Asset Turnover yoy N